BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder

Summary

This study will determine the efficacy, safety, and tolerability of a once-daily (QD) dose of up to 80 mg of BTRX-246040 for 8 weeks in participants with MDD.

Timeline

Start

2017-06-12

Primary completion

2018-11-12

Completion

2018-12-12

Outcome

Missed primary endpoint

registry analysis (other test); BTRX-246040 vs Placebo; p = 0.5939; Mean Difference (Net) -1.3 (95% CI -6.3 to 3.6); MMRM NCT03193398 ↗

Drugs

Indications